

# Afghanistan SUPPORT for INACTIVATED POLIO VACCINE (IPV)

### This Decision Letter sets out the Programme Terms of a Programme.

1.	Country: Afghanistan				
2.	rant Number: 1518-AFG-25c-X / 15-AFG-08h-Y				
3.	Date of Decision Letter: 10/07/2014				
4.	Date of the Partnership Framework Agreement: 30/04/2013				
5.	Programme Title: NVS	, IPV Routine			
6.	Vaccine type: Inactivate	ed Polio Vaccine (IPV)	)		
	Requested product pre dose(s) per vial, LIQUIE		ation of vaccine <sup>1</sup> : Inactiv	ated Polio Vaccine, 10	
8.	Programme Duration <sup>2</sup> :	2015 - 2018			
Pleas	Agreement): re note that endorsed or app g into account updated info	proved amounts for 2017	he terms of the Partners and 2018 will be communic irements and following GAV	ated in due course,	
	201:	5 2016	Total <sup>3</sup>		
Progran Budget (US\$)	us\$1,956,500	0 US\$1,761,000	US\$3,717,500		
10.	Vaccine Introduction C	Grant: US\$823,000	L		

 <sup>&</sup>lt;sup>1</sup> Please refer to section 18 for additional on IPV presentation.
<sup>2</sup> This is the entire duration of the programme.
<sup>3</sup> This is the total amount endorsed by GAVI for 2015 to 2016.



## **11.** Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup>

Type of supplies to be purchased	2015
with GAVI funds in each year	
Number of IPV vaccines doses	1,634,400
Number of AD syringes	1,078,700
Number of re-constitution	
syringes	
Number of safety boxes	11,875
Annual Amounts (US\$)	US\$1,956,500

12. Procurement agency: UNICEF

13. Self-procurement: not applicable

#### 14. Co-financing obligations:

GAVI's usual co-financing requirements do not apply to IPV. However, Afghanistan is encouraged to contribute to vaccine and/or supply costs for IPV.

#### 15. Operational support for campaigns: N/A

**16.** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	To be agreed with GAVI Secretariat in the context of GAMR Internal Appraisal for support in 2016

17. Financial Clarifications: The Country shall provide the following clarifications to GAVI\*:

\*Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements

#### 18. Other conditions:

Comment	Follow -up needed
Provide the EVM improvement plan and	Outcomes of the nationwide cold chain
implementation status as per the guidelines for	assessment including inventory of cold chain
the EVM carried out in August 2011.	equipment and the Effective Vaccine

<sup>&</sup>lt;sup>4</sup> This is the amount that GAVI has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

	Management Assessment planned should be communicated to the GAVI secretariat once available.
Provide date for revision of the cMYP to include IPV.	Country should inform GAVI about the next planning cycle beginning on March 2016 that planned to be finalized by mid-2015 for the revision of the cMYP.

If Afghanistan envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Afghanistan.

Signed by,

ditant to brift

**On behalf of the GAVI Alliance** Hind Khatib-Othman Managing Director, Country Programmes 10 July 2014